Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)
Date:12/11/2008

inhaled short-acting beta2-agonists. Administered twice daily, SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in less than or
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... May 22, 2007,/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. ... from Study 16 and,Study 17 of the ... men with erectile dysfunction (ED) were presented,yesterday ... (AUA 2007) held in Anaheim, CA. New ...
... New Data Suggests Less Abuse-Related Effects For ... Benefit of Unique OROS(r),Formulation , SAN DIEGO, ... abuse remains an,ongoing concern for parents and ... Hyperactivity Disorder,(ADHD). Data presented on Tuesday at ...
Cached Medicine Technology:Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 2Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 3Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 4Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 5Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 6Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 7New Data Focuses on Abuse of Stimulant Medication 2New Data Focuses on Abuse of Stimulant Medication 3New Data Focuses on Abuse of Stimulant Medication 4New Data Focuses on Abuse of Stimulant Medication 5
(Date:10/22/2014)... October 22, 2014 On October 22, ... featuring skin diseases both fictional and real. The ... a nonprofit organization committed to advocacy and philanthropy in ... will take the opportunity to impart truth and clarity ... , There are many misconceptions about Morgellons Disease ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 2014 During the Western United States’ ... runs dangerously low, Southern Oregon’s water is proving resistant ... the lowest mountain snow pack on record in 2014, ... early autumn.* That was the observation of journalist-hikers Art ... “Hiking Southern Oregon,” during an interview with water advocate ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... than three million babies worldwide are conceived through Assisted ... intra-uterine induction. ,In Britain, ART accounts for ... 10,242 in 2004 while many more women undergo ... is 28.2 per cent, falling to 10.6 per cent ...
... genes that are associated with resistance to chemotherapeutic drugs ... significantly enhance the ability to predict whether or ... functional genomic screen. ,Resistance to chemotherapeutic drugs ... with metastatic cancer. Dr. Julian Downward from the Cancer ...
... water or coke when thirsty; instead get a can of Tea Cola, ... still in the mood for a cup of tea , just pop ... developed the exotic health drink and the pill from tea extracts are ... granted provisional patent rights. ,"It would be a milestone in ...
... legend Sir Elton John performed a free gig in ... place in the country's capital Kiev, was attended by ... politicians. ,The charity performance of the singer ... received mixed reviews from the people, with some appreciating ...
... out of sponsoring Lindsay Lohan's birthday bash, but now another ... as well as jailed pal Paris Hilton a service ... to go clubbing or partying." ,According to the ... home after a wild night of partying and boozing. Lohan ...
... cheer to the capital with most people indulging in outdoor activities, ... ,As the city received 104.7 mm of rain in ... receives in the month of June, the city faced waterlogging problems. ... family went to India Gate to simply enjoy the weather out ...
Cached Medicine News:Health News:Questions Raised Over Safety of In-vitro Fertilization 2Health News:Questions Raised Over Safety of In-vitro Fertilization 3Health News:Questions Raised Over Safety of In-vitro Fertilization 4Health News:New Genetic Studies Carried Out in Cancer Therapy 2Health News:Tea Pill, Tea Cola Hitting Markets Soon 2
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... for Urinary Control offers a revolutionary ... the symptoms of overactive bladder, including ... of urgency-frequency alone or in combination ... could not tolerate more conservative treatments. ...
... ELPHA 4 Conti is a battery operated dual-channel ... of conditions described below. ELPHA 4 Conti also ... STRESS- and faecal incontinence ELPHA 4 Conti provokes ... the user can feel which muscles need exercising. ...
... Set is the HDR solution which duplicates ... The template set consists of a small ... to the patient and is placed in ... Face Plates. The Stepper Holder is available ...
Medicine Products: